Validation of Technology of Combined Two-Component Anti-Tb Drug "Rizef 150/75"

The Journal of scientific articles "Health and Education millennium"
doi 10.26787/nydha-2226-7425-2017-19-12-292-296
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Network of Young Doctors and Health Administrators

Related search

Crystal Structures of Membrane Transporter MmpL3, an Anti-Tb Drug Target

Cell
BiochemistryGeneticsMolecular Biology
2019English

Anti-Cancer Drug Validation: The Contribution of Tissue Engineered Models

Stem Cell Reviews and Reports
2017English

Improper Anti-Tb Treatment- Almost Certain Recipe for MDR-Tb

Journal of Evolution of Medical and Dental Sciences
2018English

Heightened Vulnerability to MDR-TB Epidemics After Controlling Drug-Susceptible TB

PLoS ONE
Multidisciplinary
2010English

Bioorthogonal Two-Component Drug Delivery in HER2(+) Breast Cancer Mouse Models

Scientific Reports
Multidisciplinary
2016English

Russia: Drug-Resistant TB Can Be Contained

Nature
Multidisciplinary
2014English

Phage Amplification Technology and Anti-Tuberculous Drug Susceptibility Testing in Nigeria

African Journal of Clinical and Experimental Microbiology
2003English

Multy-Drug Resistant Tb and Extensively Resistant Tb: Who Materials in Publications of the Russian Authors

Social Aspects of Population Health
2019English

Online Validation of Combined Mood Induction Procedures

PLoS ONE
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy